Vita Genomics Inc (賽亞基因科技), Taiwan’s biggest genomics-based biotechnological and biopharmaceutical company, aims to double its profits this year through the acquisition of domestic testing facilities and partnerships with global drug makers, company executives said yesterday.
The New Taipei City-based company recorded a modest NT$103 million (US$3.3 million) in net income last year, translating into earnings per share of NT$2.37, according to the company’s Web site.
The figures represent an end to 13 years of losses after the unlisted company last year recruited Vita Genomics general manager Eddy Hsieh (謝春成), who introduced a financial restructuring plan and shut down unprofitable businesses.
Hsieh also helped the company recognize intangible assets, including establishing a database among other innovations, the company said.
The process of reinvention is set to continue, with a capital increase plan slated for June, with which the company hopes to raise about NT$800 million by issuing 60,000 common shares priced at NT$13 per share, Hsieh said.
The capital injection is almost twice the current capitalization of NT$460 million.
Domestic and foreign hedge funds have voiced interest in purchasing the 13-year-old company’s stock.
“Vita Genomics plans to use the money to develop into a healthcare services provider, integrating firms in the supply chain,” Hsieh said.
The company is set to increase its pharmaceutical partners from four to seven and has inked three-year cooperation agreements with five global drug makers, Vita Genomics said, without disclosing details.
The partnerships are set to allow the company to move into the companion test business, boosting its corporate value, Hsieh said.
In Taiwan, Vita Genomics has struck acquisition deals with five genomics testing facilities and is in talks to buy a large pathology-testing laboratory later this year, the company said.
“The testing business should be a key profit driver this year after the integration,” Hsieh said.
The testing business now generates NT$200 million in revenue, the company said, adding that the amount is expected to double in the second quarter and approach NT$600 million in the second half.
In addition, Vita Genomics has built strong relationships with research institutions and medical organizations throughout the nation.
The company is an active participant in modernizing the nation’s healthcare system and is establishing the infrastructure needed to add molecular profile information to the National Health Insurance IC card.
Vita Genomics is also plans set up a healthcare team that would help conduct annual checkups of students and workers at schools and private companies, the company said, adding that the venture could generate another NT$100 million in revenue.
PATENTS: MediaTek Inc said it would not comment on ongoing legal cases, but does not expect the legal action by Huawei to affect its business operations Smartphone integrated chips designer MediaTek Inc (聯發科) on Friday said that a lawsuit filed by Chinese smartphone brand Huawei Technologies Co (華為) over alleged patent infringements would have little impact on its operations. In an announcement posted on the Taiwan Stock Exchange, MediaTek said that it would not comment on an ongoing legal case. However, the company said that Huawei’s legal action would have little impact on its operations. MediaTek’s statement came after China-based PRIP Research said on Thursday that Huawei filed a lawsuit with a Chinese district court claiming that MediaTek infringed on its patents. The infringement mentioned in the lawsuit likely involved
Taipei is today suspending work, classes and its US$2.4 trillion stock market as Typhoon Gaemi approaches Taiwan with strong winds and heavy rain. The nation is not conducting securities, currency or fixed income trading, statements from its stock and currency exchanges said. Authorities had yesterday issued a warning that the storm could affect people on land and canceled some ship crossings and domestic flights. Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) expects its local chipmaking fabs to maintain normal production, the company said in an e-mailed statement. The main chipmaker for Apple Inc and Nvidia Corp said it has activated routine typhoon alert
GROWTH: TSMC increased its projected revenue growth for this year to more than 25 percent, citing stronger-than-expected demand for AI devices and smartphones The Taiwan Institute of Economic Research (TIER, 台灣經濟研究院) yesterday raised its forecast for Taiwan’s GDP growth this year from 3.29 percent to 3.85 percent, as exports and private investment recovered faster than it predicted three months ago. The Taipei-based think tank also expects that Taiwan would see a 8.19 percent increase in exports this year, better than the 7.55 percent it projected in April, as US technology giants spent more money on artificial intelligence (AI) infrastructure and development. “There will be more AI servers going forward, but it remains to be seen if the momentum would extend to personal computers, smartphones and
CHANGE OF FORTUNES: Concern over a pricey valuation and the risk of tighter US curbs on chip sales to China have poured cold water on TSMC’s bullish momentum Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) shares fell the most in three months yesterday upon trading resumption, joining a global technology rout as investors dramatically soured on the promises of artificial intelligence (AI). The shares declined 5.62 percent to close at NT$924 in Taipei, dragging down the benchmark TAIEX, which fell 3.29 percent to 22,119.21 points amid a technical correction, Taiwan Stock Exchange data showed. Other chip stocks also fell, with ASE Technology Holding Co (日月光投控) plunging 9.86 percent, MediaTek Inc (聯發科) dropping 2.35 percent, Realtek Semiconductor Corp (瑞昱) falling 1.33 percent and United Microelectronics Corp (聯電) retreating 1.17 percent, while Apple